PF-02575799 structure
|
Common Name | PF-02575799 | ||
|---|---|---|---|---|
| CAS Number | 863491-70-7 | Molecular Weight | 680.76600 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C42H37FN4O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PF-02575799PF-02575799 is a microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 0.77±0.29 nM. |
| Name | N-[(1S)-2-[(4-fluorophenyl)methyl-methylamino]-2-oxo-1-phenylethyl]-2-[[2-(4-propan-2-yloxyphenyl)benzoyl]amino]quinoline-6-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | PF-02575799 is a microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 0.77±0.29 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.77±0.29 nM (MTP)[1] |
| In Vitro | PF-02575799 is compound 13 from the reference[1]. |
| In Vivo | PF-02575799 produces appreciable triglyceride effects at its minimally effective dose (10 mg/kg). PF-02575799 significant increase alanine transaminase at 100 mg/kg[1]. |
| Animal Admin | Rats[1] Spray-dried dispersions formulated PF-02575799 is tested in a seven-day rat model. Food intake, body weight, liver TG, as well as serum alanine transaminase (ALT) are measured. In the definitive study, dose effect relationships are examined (PF-02575799 1, 3, 10, 30 and 100 mg/kg q.d.) and systemic exposures are measured[1]. |
| References |
| Molecular Formula | C42H37FN4O4 |
|---|---|
| Molecular Weight | 680.76600 |
| Exact Mass | 680.28000 |
| PSA | 103.86000 |
| LogP | 8.02290 |
| InChIKey | HMTLPJFACYNTHS-KDXMTYKHSA-N |
| SMILES | CC(C)Oc1ccc(-c2ccccc2C(=O)Nc2ccc3cc(C(=O)NC(C(=O)N(C)Cc4ccc(F)cc4)c4ccccc4)ccc3n2)cc1 |
| unii-i6kf9af7f7 |
| PF-02575799 |